₹49.19 Crores | Listing at BSE | Wed, Apr 30, 2025 - Wed, May 14, 2025
Remedium Lifecare Limited Rights Issue comprises 49.19 Cr equity shares aggregating to ₹49.19 Cr, offered at an issue price of ₹1 per share with a face value of ₹1 per share.
The record date for determining eligible shareholder is Apr 15, 2025, with the Rights Issue being offered in the entitlement ratio of 61 : 50.
The term of payment is defined as following : Full amount of the Issue Price will be payable on application
The Rights Entitlements are expected to be credited to eligible demat accounts on [.]
The Rights Issue opens on Apr 30, 2025, and closes on May 14, 2025, with renunciation of Rights Entitlements permitted up to May 9, 2025.
The deemed date of allotment is Apr 26, 2025, following which the equity shares are expected to be credited to demat accounts on May 28, 2025 and listed at the BSE on Jun 5, 2025.
Bigshare Services Pvt.Ltd. is the Registrar to the Issue.
Investors are advised to refer to the Remedium Lifecare Limited Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.
Record Date
Tue, Apr 15, 2025
Entitlement Ratio
61 : 50
Open Date
Wed, Apr 30, 2025
Close Date
Wed, May 14, 2025
Full amount of the Issue Price will be payable on application
| Period Ended | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 1,947.92 | 1,154.22 |
| Revenue | 4,062.79 | 509.84 |
| Profit After Tax | 32.73 | 5.43 |
| Amount in ₹ Crore | ||
Incorporated in 1988, Remedium Lifecare Limited, formerly known as Roxy Exports Limited, is a Mumbai-based pharmaceutical company.
The company specializes in the trading and sale of Active Pharmaceutical Ingredients (APIs) and intermediates, Remedium serves both domestic and international markets.
The company has been trading and distributing pharmaceutical raw materials, including amino isophthalic acid, tellurium (IV) oxide, iodine, selenium metal powder, and lithium intermediates since 2020, with strong supply chain capabilities.
As on December 31, 2024, the company have the total strength of permanent employees 8 in various departments.
The Company proposes to utilize the Net Proceeds towards the following objects:
[Dilip Davda] RLL is a trader/distributor of wide range of raw material utilized for pharmaceuticals, and other related chemicals. The company posted inconsistency in its top and bottom lines for the reported periods. It is operating in a highly competitive and fragmented segment. Though at par, the RI appears fully priced, counter we well managed above RI price to lure investors. There is no harm in skipping this “High Risk/Low Return” at par bet. Read detail review...
Remedium Lifecare Rights Issue 2025 got oversubscribed by 1.05 times by the end of the bidding period with total bid quantity received by BSE of 51,85,89,761 shares. Check Day by Day Subscription Details (Live Status)
| Date | BSE Bid Quantity | Subscription Times |
|---|---|---|
May 14 2025 17:00:00 | 51,85,89,761 | 1.05x |
Remedium Lifecare Limited
Office No 9, K Raheja Prime, Marol Industrial,
Marol Industrial Estate, Behind Ravi Vihar Hotel,
Sagbaug Road, Andheri East, Marol Naka, 400059
Andheri, Maharashtra, 400059
The Remedium Lifecare Rights Issue 2025 opens on Wed, Apr 30, 2025, and closes on Wed, May 14, 2025.
Remedium Lifecare Rights Issue 2025 Schedule
| Last Date for credit of Rights Entitlements | |
| Last Date for renunciation of Rights Entitlements | Fri, May 9, 2025 |
| Issue Opening Date | Wed, Apr 30, 2025 |
| Issue Closing Date | Wed, May 14, 2025 |
| Date of Allotment (on or about) | Sat, Apr 26, 2025 |
| Date of Credit (on or about) | Wed, May 28, 2025 |
| Date of Listing (on or about) | Thu, Jun 5, 2025 |
You can apply for Remedium Lifecare Rights Issue 2025 in two ways:
Steps to apply for Remedium Lifecare Rights Issue 2025 using Net Banking (ASBA)
Steps to apply for Remedium Lifecare Rights Issue 2025 using Registrar's website (R-WAP)
